Created byFuzzy Cloud

Legislation

Patents Act, 1970

11 Supreme Court judgments cite this Act.

IN RE: DISTRIBUTION OF ESSENTIAL SUPPLIES AND SERVICES DURING PANDEMICversus.

2021 INSC 30231 May 2021Directions issued

The Supreme Court, hearing a suo motu writ petition concerning the management of the COVID‑19 pandemic, examined the Central Government's Liberalised Vaccination Policy, which shifted free vaccination for the 18‑44 age group to State/UT governments and private hospitals and introduced differential pricing. The petition

IN RE: DISTRIBUTION OF ESSENTIAL SUPPLIES AND SERVICES DURING PANDEMICversus.

2021 INSC 28030 April 2021Directions issued

The Supreme Court, exercising suo motu jurisdiction under Article 32, examined the humanitarian crisis caused by the COVID-19 pandemic and issued directions to the Union and State governments on the supply of oxygen, essential drugs, and vaccines, as well as on hospital admission policies and protection of individuals

CIPLA LTD.versusUNION OF INDIA & ORS.

2012 INSC 54227 November 2012Disposed off

Sugen Inc. and Pharmacia & Upjohn were granted Indian Patent No. 209251 for a pharmaceutical invention. Cipla Ltd. filed an opposition under Section 25(2) of the Patents Act, 1970, and the Controller revoked the patent on 24 September 2012 relying on the Opposition Board’s recommendation, but without furnishing the Boa

J. MITRA & CO. PVT. LTD.versusASST. CONTROLLER OF PATENTS & DESIG. & ORS.

2008 INSC 95821 August 2008Disposed off

J. Mitra & Co. Pvt. Ltd. applied for a patent which was opposed by Span Diagnostics Ltd. (respondent No.3). The opposition was initially a pre‑grant opposition under Section 25(1) of the Patents Act, 1970. The Controller rejected the pre‑grant opposition on 23‑Aug‑2006 and the respondent filed appeals (FAO Nos. 292/06

SHARAT BABU DIGUMARTIversusGOVT. OF NCT OF DELHI

2016 INSC 113114 December 2016Appeal(s) allowed

The appellant, Sharad Babu Digumarti, was charged under IPC Sections 292 and 294 and IT Act Section 67 for alleged possession of obscene material in electronic form. He was discharged of the IT Act charge but the trial court framed a charge under IPC Section 292, which the High Court upheld. The Supreme Court examined

GLAXO SMITH KLINE PLC AND ORS.versusCONTROLLER OF PATENTS & DESIGNS AND ORS.

2008 INSC 102810 September 2008Appeal(s) allowed

Glaxo Smith Kline PLC and others applied for a patent and an Exclusive Marketing Right (EMR) in 1998‑2000. The Controller of Patents rejected the EMR in 2002; the applicants filed writ petitions and a Calcutta High Court Single Judge set aside the rejection and remanded the matter. The Controller again rejected the EMR

S.M. DYECHEM LTD.versusCADBURY (INDIA) LTD.

2000 INSC 3129 May 2000Dismissed

S.M. Dyachem Ltd. (plaintiff) claimed that its registered trademark “PIKNIK” for food products was infringed by Cadbury (India) Ltd.’s use of “PICNIC” on chocolates and sought a temporary injunction. The High Court set aside the trial court’s injunction, holding that the marks differed in essential features and there w

MONSANTO TECHNOLOGY LLC THRU THE AUTHORISED REPRESENTATIVE MS. NATALIA VORUZ & OTHERSversusNUZIVEEDU SEEDS LTD. THRU THE DIRECTOR & OTHERS

2019 INSC 358 January 2019Disposed off

Monsanto Technology LLC sued Nuziveedu Seeds Ltd. for permanent and temporary injunctions alleging infringement of its patented cotton biotechnology (patent No. 214436) and misuse of its trademarks. The defendants filed a counter‑claim under Section 64 of the Patents Act seeking revocation of the patent on the ground t

DR. ALOYS WOBBEN & ANR.versusYOGESH MEHRA & ORS.

2014 INSC 4162 June 2014Disposed off

Dr. Aloys Wobben, holder of several wind‑turbine patents, sued Yogesh Mehra and others for patent infringement in the Delhi High Court. The respondents filed revocation petitions before the Intellectual Property Appellate Board under s.64(1) of the Patents Act and also raised counter‑claims in the infringement suits se

NOVARTIS AGversusUNION OF INDIA & OTHERS

2013 INSC 1981 April 2013Disposed off

Novartis AG sought a product patent in India for the beta‑crystalline form of imatinib mesylate (Gleevec). The patent office rejected the application on grounds of lack of novelty, obviousness and failure to satisfy the enhanced‑efficacy requirement of section 3(d) of the Patents Act, 1970. Novartis appealed directly t

Search Indian case law

Ask in plain English, not just keywords. 25,000 AI words free, no card.

Search by issue, statute, judge or citationSign in to search